Navigation Links
Treatments have same target, different responses for lung cancer patients with genetic mutation

The gene mutation that identifies the lung cancer patients most likely to respond to the drug gefitinib (Iressa) is not associated with a response to the drug cetuximab (Erbitux), according to a new study published in the August 17 issue of the Journal of the National Cancer Institute. Both drugs target the same gene but through different mechanisms.

Some patients with non�small-cell lung cancer (NSCLC) have mutant versions of the epidermal growth factor receptor (EGFR). This protein activates signaling pathways involved with cell growth and survival. Previous studies have shown that small-molecule EGFR inhibitors such as gefitinib and erlotinib (Tarceva) work by blocking signals in the intracellular domain of EGFR--between the EGFR and the cell nucleus. Additionally, many NSCLC patients with mutations in this intracellular domain of EGFR appear to benefit from these drugs.

Toru Mukohara, M.D., of the Dana-Farber Cancer Institute in Boston, and colleagues decided to examine the effectiveness of another type of drug that targets EGFR--a monoclonal antibody called cetuximab, which is approved for the treatment of metastatic colorectal cancers that overexpress EGFR. Cetuximab targets EGFR by preventing its activation by extracellular signals, or signals occurring outside of the cell, as opposed to the intra-cellular signal blocking of drugs like gefitinib.

The researchers treated seven different NSCLC cell lines with cetuximab or gefitinib, and compared the drugs' effects on cell growth and cell death or apoptosis. They found that both drugs similarly inhibited the growth of the NSCLC cells containing the normal form of EGFR. However, gefitinib was more effective than cetuximab at inhibiting cell growth and increasing apoptosis in NSCLC cells with mutant EGFR.

The authors note that because these studies were carried out in cell lines, and not in humans, issues such as which drug has more toxicity or negative side effects are still unanswered. However, they did examine the outcomes of four patients with EGFR mutations in their tumors who had been treated with gefitinib and then cetuximab, or vice versa. They found that all patients displayed partial responses to gefitinib in terms of tumor shrinkage, whereas none of them appeared to respond to cetuximab.

"Overall, our results raise the possibility that NSCLC patients with EGFR mutations may derive the greatest benefit, in terms of tumor regression, if treated with gefitinib rather than with cetuximab," the authors conclude.

"These findings clearly have important clinical implications because both drugs should, theoretically, block EGFR signaling," writes John D. Minna, M.D., of the Hamon Center for Therapeutic Oncology Research at the University of Texas Southwestern Medical Center in Dallas, and colleagues in an accompanying editorial. "The first round clearly was won by [drugs such as gefitinib]." However, they add that additional research should focus on the effects of cetuximab on certain populations of patients, or used in conjunction with other drugs. "Cetuximab may still have an effective punch if the right circumstances can be identified," the authors conclude.


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
2. Effective Cancer Treatments Follow The Clock
3. Natural Killers Could Lead to New Hepatitis Treatments
4. Minimally Invasive Cancer Treatments Highlighted
5. Two designer drugs hit same lung cancer target, but only one is effective
6. Scientists discover how fish evolved to float at different sea depths
7. Genetics links whale to two different ocean basins
8. Stem cells bring fast direct improvement, without differentiation, in acute renal failure
9. Tiny roundworms telomeres help scientists to tease apart different types of aging
10. Tissue regeneration operates differently than expected
11. Human cerebellum and cortex age in very different ways
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell , ... technology, and STMicroelectronics (NYSE: STM), a global ... electronics applications, announced today the launch of a ... biometric wearables that includes ST,s compact SensorTile ... Benchmark™ biometric sensor system. Together, SensorTile and ...
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... Cleveleys, UK (PRWEB) , ... ... ... results presented by surgeons at the 2016 annual meeting of the North ... beneficial clinical outcomes, for patients in the majority of cases, when PEEK-OPTIMA™ ...
(Date:1/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... a global Phase 2b induction study in ulcerative ... alpha4beta7 integrin. The aim of this randomized, double-blind, ... safety/tolerability and efficacy of PTG-100 in approximately 240 ... active disease. "We are very ...
(Date:1/16/2017)... 16, 2017  Eurofins Genomics today announced the expansion ... customers to receive their primers in a shorter turnaround ... quality found with other providers. Express oligos are available ... at no additional fee. Researchers use ... including DNA sequencing, genotyping, site-directed mutagenesis, and cloning. Often, ...
(Date:1/13/2017)... ... January 13, 2017 , ... Two ... organic compound called fulvic acid that farms, greenhouses and hydroponics operations use to ... are among the fastest growing segments of customers using this high grade fulvic ...
Breaking Biology Technology: